Evidence profile of RCTs examining the effect of CCB vs. placebo in transplant recipients without DM. Supplementary Table 58. RCTs examining the effect of CCB vs. placebo in transplant recipients [categorical outcome]. Supplementary Table 59. RCTs examining the effect of CCB vs. placebo in transplant recipients without DM [continuous outcome]. Supplementary Table 60. RCTs examining the effect of ACE vs. ARB in hypertensive transplant recipients without DM [continuous out- comes]. Supplementary Table 61. RCTs examining the effect of ARB vs. placebo in transplant recipients [categorical outcome]. Supplementary Table 62. RCTs examining the effect of ARB vs. placebo in transplant recipients without DM [continuous outcome]. Supplementary material is linked to the online version of the paper at http://www.kdigo.org/clinical_practice_guidelines/bp.php Chapter 6: Blood pressure management in children with CKD ND INTRODUCTION This chapter addresses the management of BP in children (defined as 18 years or younger, although chronological age does not necessarily parallel biological or social development). Children with non-dialysis-dependent CKD (CKD ND) differ from adults in the etiologies of CKD, definition of hyperten- sion, and CKD associated co-morbidities. As cardiovascular end points such as myocardial infarction, stroke, or cardio- vascular death are rare, effects of high BP and its treatment on kidney outcomes (e.g., lowering of GFR, initiation of dialysis, or transplantation) and target-organ damage are relevant end points in studies of children with CKD, although in the longer-term, CVD has a more important role. Elevated BP and high BP are common in children with CKD, but RCTs of various treatment agents or targets are scarce. Observational studies and registry data311 315 demon- strate that more than half of children with CKD have high BP based upon a casual BP reading. 